- Research article
- Open Access
- Open Peer Review
Rhodiola crenulata extract for prevention of acute mountain sickness: a randomized, double-blind, placebo-controlled, crossover trial
© Chiu et al.; licensee BioMed Central Ltd. 2013
- Received: 10 April 2013
- Accepted: 28 October 2013
- Published: 31 October 2013
Rhodiola crenulata (R. crenulata) is widely used to prevent acute mountain sickness in the Himalayan areas and in Tibet, but no scientific studies have previously examined its effectiveness. We conducted a randomized, double-blind, placebo-controlled crossover study to investigate its efficacy in acute mountain sickness prevention.
Healthy adult volunteers were randomized to 2 treatment sequences, receiving either 800 mg R. crenulata extract or placebo daily for 7 days before ascent and 2 days during mountaineering, before crossing over to the alternate treatment after a 3-month wash-out period. Participants ascended rapidly from 250 m to 3421 m on two separate occasions: December 2010 and April 2011. The primary outcome measure was the incidence of acute mountain sickness, as defined by a Lake Louise score ≥ 3, with headache and at least one of the symptoms of nausea or vomiting, fatigue, dizziness, or difficulty sleeping.
One hundred and two participants completed the trial. There were no demographic differences between individuals taking Rhodiola-placebo and those taking placebo-Rhodiola. No significant differences in the incidence of acute mountain sickness were found between R. crenulata extract and placebo groups (all 60.8%; adjusted odds ratio (AOR) = 1.02, 95% confidence interval (CI) = 0.69–1.52). The incidence of severe acute mountain sickness in Rhodiola extract vs. placebo groups was 35.3% vs. 29.4% (AOR = 1.42, 95% CI = 0.90–2.25).
R. crenulata extract was not effective in reducing the incidence or severity of acute mountain sickness as compared to placebo.
- Acute mountain sickness
- High altitude illness
Acute mountain sickness (AMS) occurs in individuals rapidly ascending to high altitude and it usually results in headache, along with anorexia or nausea, fatigue, dizziness, and insomnia. The number of people travelling rapidly to higher altitudes for work or recreation is rising. As a result of improvements in transportation to these high-altitude regions, AMS has become a significant environmental health issue. The most effective preventive method for AMS—gradual ascent—is usually difficult or impractical for modern international travelers to locations such as Lhasa in Tibet (3650 m) and La Paz in Bolivia (3740 m). The pathophysiology of AMS is not totally understood but it is apparent that administration of prophylactic treatments is helpful. Historically acetazolamide has been used as a gold standard in treatments to prevent malaise symptoms at high altitudes[1, 2, 4–7]. However, acetazolamide requires a prescription and has side effects such as paresthesia, dysgeusia, and diuresis[2, 8, 9]. Some over-the-counter herbal supplements such as Rhodiola species, Ginkgo biloba and Coca leaf products are widely used[3, 5, 7, 10–17].
Genus Rhodiola (family Crassulaceae) has been a valuable medical plant in European countries for thousands of years[10, 18, 19]. There are more than ninety species worldwide and they are well known for their high antioxidant activities. Different species of Rhodiola differ in their content of bioactive components and medicinal use in indigenous regions. To date, most studies focus on the efficacy of Rhodiola rosea in treating physical and mental fatigue. Of all the known Rhodiola species, Rhodiola crenulata (R. crenulata) is particularly described in the Pharmacopoeia of China and is considered as the highest in quality. Also, it has been used for treating acute mountain sickness in Tibet since ancient times.
Pulmonary alveolar hypoxia, a common phenomenon for non-acclimatized individuals who abruptly relocate to a high altitude, is thought to contribute to the impaired trans-alveolar fluid transport. The excessive fluid that subsequently accumulates in alveoli exaggerates alveolar hypoxia and obstructs the gas exchange process, leading to the pathological progression of high altitude pulmonary edema, the most lethal form of high-altitude illnesses[21, 22]. In a rodent model, R. crenulata extract exhibited a high antioxidant activity and attenuated pulmonary edema induced by hypobaric hypoxia. Recent studies have shown that Na/K-ATPase plays a key role in alveolar fluid clearance. Both inhibition and knockdown of Na/K-ATPase expression significantly reduced the alveolar fluid clearance in rodent models[23, 24]. Two bioactive components of R. crenulata, salidroside and tyrosol, were shown to hold antioxidant, anti-depression, anti-fatigue, and anti-inflammatory activities[25–30]. Therefore, the capabilities of R. crenulata in preventing the hypoxia-mediated Na/K-ATPase endocytosis and maintaining the integrity of alveolar-capillary barrier and pulmonary sodium transport might be the underlying mechanisms of its effect against pulmonary edema in rodent models.
Although R. crenulata is widely used to prevent AMS in the Himalayan areas and in Tibet[20, 32], but no scientific studies have examined its effectiveness in humans. We conducted a controlled study to investigate the efficacy of R. crenulata in AMS prevention. In the clinical trials for Rhodiola, most studies were conducted to investigate whether Rhodiola could improve the endurance exercise performance or protect against fatigue. The daily dosage of Rhodiola extract tested was mostly under 500 mg (ranged between 100–972 mg)[15, 18, 19]. Regarding the duration of prophylactic medication for AMS, chemical drugs such as acetazolamide could elicit a quick response and were usually administered on the day before or prior to the ascent. In the trials on AMS prevention using prophylactic herbal medication, Ginkgo biloba was the one mostly studied. It was often administered for one to five days prior to the ascent[3, 11–13]. Considering the onset of AMS after ascent and the compliance of prophylactic medication, a high dose of R. crenulata (800 mg daily) was chosen in this study and the subjects were administered with R. crenulata for seven days prior to the ascent.
This study has been approved by the Institutional Review Board (IRB) of Chang Gung Medical Foundation, Linkou Medical Center, Taoyuan, Taiwan. The IRB approved number is "99-3057C" and the topic is titled "Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness". Subjects were given written information and a verbal explanation concerning the study prior to obtaining the written informed consent for their participation.
We included local Chinese adults aged 23 to 55 years who resided principally at an elevation of 250 m or lower. We excluded those who (1) would not complete the study protocol of two 9-day treatment courses; (2) had prophylactic medication or herbs one month before each ascent (including acetazolamide, sildenafil, tadalafil, dexamethasone, nifedipine, Rhodiola species, Ginkgo biloba, Eleuthero Root, Salvia miltiorrhiza, and sea buckthorn); (3) change in altitude of residence for more than 200 m between ascents; (4) had additional physical training or were scheduled to gain or lose weight; (5) had altitude exposure above 2500 m within three months prior to each ascent; (6) had any history of chronic obstructive pulmonary disease, heart failure, cerebral neoplasm, mania, renal or hepatic insufficiency; or (7) were pregnant or intended to become pregnant during the 3-month study period. After baseline assessment, the subjects were randomly assigned into either sequence.
Study design, randomization and blinding
This study was a randomized, double-blind, placebo-controlled and crossover trial. Subjects were randomized to 2 treatment sequences, receiving either the R. crenulata or the placebo, and then crossed over to the alternate treatment after a 3 month wash-out period. Random numbers were generated by using the computer, using block randomization with a block size of 2 or 4. The random numbers were placed in sealed envelopes, and a serial number was assigned to each envelope according to the sequence of allocation of the randomized number. Each envelope was then opened sequentially, according to the admission sequence of the participants at the study center. The number inside the envelope determined the treatment sequence that each participant was allocated to (Rhodiola-placebo or placebo-Rhodiola). Both investigators and participants were blinded. One investigator, who was not responsible for any assessment, enrolled all participants and allocated them to treatment. Blinding was maintained until the data analysis was complete.
Commercial pharmaceutical grade R. crenulata and placebo were packed by Kaiser Pharmaceutical & Biotanico (Tainan, Taiwan). Both were pink soft gelatin capsules (400 mg/capsule) in identical containers and there were no differences in the taste or smell of the capsules. The standardized R. crenulata extract (with 2.38% salidroside and 0.44% p-tyrosol) was manufactured from the same batch of raw materials[33, 34]. The origin of the herb was authenticated by microscopic identification and sequence analysis of the internal transcribed spacer regions. The material was examined for microorganisms, heavy metals, and pesticide according to the accepted standards (good manufacturing practice, GMP) of Taiwan. Each participant received a high dose (800 mg) of R. crenulata or placebo (800 mg) daily for 9 days. Beginning 7 days before an ascent, participants were required to inform the investigators by email or telephone every day about the study capsule supply or any adverse effects. If the investigators were not contacted before noon, they would follow up by phone to obtain this information. Moreover, the participants were requested to take capsules every morning of their 2-day mountaineering trip.
The Lake Louise scoring system (LLS)—a simple and widely accepted tool developed by the Lake Louise Consensus Group[1, 35]—was used to assess the AMS grade. The LLS rates 5 symptoms (headache, gastrointestinal symptoms such as nausea and vomiting, fatigue and/or weakness, dizziness and/or light-headedness, and difficulty sleeping) on a self-report questionnaire, with each item graded on a scale from 0 to 3. Thus, the LLS scores can range from 0 (no symptoms or signs) to 15 (the worst rating on each symptom)[12, 13, 35].
The AMS grade, Lake Louise self-report questionnaire, and pulse oximetry (SpO2, NPB 40, Nellcor, Pleasanton, CA, USA) were completed at 10 checkpoints along the route. Four emergency physicians, familiar with the management of AMS, took care of any discomfort of the participants during the whole course of mountaineering. Participants were not permitted to self-treat their AMS symptoms. Instead, they were told in advance that investigators would provide oral acetaminophen (500 mg) or ibuprofen (400 mg) for headache, meclizine (25 mg) for dizziness or intramuscular prochlorperazine (5 mg) for nausea and/or vomiting.
All subjects had their own mountaineering health passport. It had a list of symptoms related to AMS, advice and precautions to take during mountaineering, a place to record pulse oximetry values, and the Lake Louise questionnaire (to be filled out at each checkpoint). It was also used to record clinical problems and treatment.
The predetermined primary outcome was the incidence of AMS. It was evaluated at checkpoints 3 to 8 (altitude above 2500 m) or at any time of discomfort after ascent. AMS was defined as LLS score ≥ 3 with headache and at least one of the symptoms of nausea or vomiting, fatigue, dizziness, or difficulty sleeping. Predetermined secondary outcomes included incidence of severe acute mountain sickness (LLS score ≥ 5), incidence of headache and severe headache (defined as a headache score of 2 or 3 on the headache item of LLS), oxygen saturation by pulse oximetry (SpO2) at checkpoint 4 (3100 m) and its difference between altitudes 250 m and 3100 m (∆SpO2: SpO2 measured at checkpoint 1 minus SpO2 at checkpoint 4).
The incidence of AMS in placebo group was hypothesized as 36% according to our previous survey. A relative risk reduction of 30% was considered the clinically significant effect in this type of treatment. According to the study design, assuming the absence of carry-over or period effects, a sample size of 133 participants was deemed sufficient to provide a power of 80% with a two-sided alpha level of 0.1 and a probability of discordant pairs of 0.7 to detect an odds ratio for the incidence of AMS of 0.59 between the Rhodiola group and the placebo group.
Baseline characteristics are presented as mean ± SD (standard deviation) or counts (percentages), as appropriate. For each variable, participants were grouped according to sequence (Rhodiola-placebo or placebo-Rhodiola) to make the baseline comparison. Comparisons between the two sequences were analyzed by the two-sample independent t test for continuous variables and Chi-square test/ Fisher exact test for categorical variables. Carry-over effects and period effects were assessed using the generalized linear models with generalized estimating equations, assuming a logit link function and an unstructured correlation.
If neither a period nor a carry-over effect occurred, paired t test or McNemar test was used to test the treatment effect. Otherwise, the generalized linear models with generalized estimating equations were used to analyze the treatment effect, assuming a logit link function and an unstructured correlation for binary outcomes or an identity link function and an unstructured correlation for continuous outcomes, and assuming adjustment for period and carry-over effects in the model. All statistical assessments were evaluated at a two-sided significance level of 0.05. Analyses were performed with SAS software package, version 9.2 (SAS Institute Inc., Cary, NC, USA).
Ambient temperatures during the four ascents
Dec. 03, 2010
Dec. 12, 2010
Apr. 08, 2011
May 03, 2011
Placebo – Rhodiola
(N = 48)
(N = 54)
35.8 ± 10.0
36.3 ± 10.4
22.6 ± 2.9
23.4 ± 3.0
98.8 ± 0.9
98.9 ± 1.0
Heart rate, beats/min
72.5 ± 8.9
72.2 ± 9.6
Altitude of residence, m
151.7 ± 105.9
152.7 ± 105.9
History of mountaineering above 3000 m
History of AMS
Period effect and carry-over effect
There was a significant difference in the incidence of AMS between period 2 (55.9%; 57/102) and period 1 (65.7%; 67/102) (odds ratio: 0.66, 95% confidence interval: 0.45 ~ 0.98). A period effect (P = 0.040) was observed for the primary outcome, but no carry-over effect was found (P = 0.877).
Major outcome measures
1.02 (0.69, 1.52) ††
1.42 (0.90, 2.25) ††
1.17 (0.75, 1.83) ††
1.16 (0.71, 1.89) ††
88.6 ± 3.9
88.6 ± 4.3
–0.13 (–0.93, 0.66) ‡‡
9.6 ± 3.8
9.5 ± 4.2
0.16 (–0.65, 0.97) ‡‡
Pulse rate, /mine
99.2 ± 14.6
99.8 ± 14.2
–0.30 (–2.61, 2.02) ‡‡
Other clinical measures
AMS symptoms scoref
1.17 ± 0.81
1.13 ± 0.83
0.05 (-0.10, 0.20) ‡‡
0.87 ± 0.82
0.79 ± 0.79
0.09 (-0.06, 0.25) ‡‡
0.94 ± 0.81
0.99 ± 0.84
–0.02 (–0.17, 0.13) ‡‡
0.52 ± 0.70
0.41 ± 0.62
0.12 (–0.01, 0.25) ‡‡
1.45 ± 0.99
1.55 ± 0.96
–0.07 (–0.29, 0.14) ‡‡
3.84 ± 2.49
3.77 ± 2.54
0.19 (-0.27, 0.55) ‡‡
After adjustment for period effect, between-group differences in the incidence of severe AMS, headache, severe headache, SpO2 level and pulse rate at checkpoint 4, and ∆SpO2 level were not significant (all P > 0.05) (Table 3).
Other outcome measures and adverse events
There were no significant differences between Rhodiola groups and placebo groups for the comparison of the worst AMS symptom scores and highest LLS scores in the interval between checkpoints 3 and 8 (all P > 0.05) (Table 3). The number of subjects requesting medication for headache/dizziness/nausea (vomiting) was about the same in both groups (36/20/4 vs. 35/20/3 for Rhodiola and placebo respectively).
Adverse events in groups receiving prophylactic agents for AMS
Rhodiola(n = 102)
Placebo (n = 102)
Difficulty in falling asleep
Assessment of blinding
After the second trip, all participants were asked to guess the trip in which they had taken Rhodiola; 49% (50/102) guessed correctly, indicating that the participants identified the treatment period during which they received Rhodiola or placebo only by chance.
R. crenulata extract was not effective in reducing the incidence or severity of AMS when compared with placebo and failed to show a protective benefit for any outcome measure examined. Statistical analyses showed that there was a period effect but no carry-over effect. AMS occurred significantly less frequently on the second mountaineering trip (65.7% vs. 55.9%; P = 0.040), regardless of treatment. Since most participants (58%) had no high-altitude mountaineering experience prior to the first trip, the first trip experience helped them adapt to conditions on the second trip in period 2. Inadequate high-altitude mountaineering experience was proven to be an independent risk factor for AMS[36–39]. In Gaillard’s study, the understanding and awareness of AMS among trekkers reduced the incidence of AMS. Also, Vardy et al. suggested that AMS is less likely to take place with a correct awareness of its symptoms and prevention. In our study, the participants filled the Lake Louise self-report questionnaire at 10 checkpoints during mountaineering, so they had a comprehensive awareness of high altitude experience and AMS symptoms after the first period of mountaineering. They also shared experiences and methods on AMS prevention, such as avoiding high impact activity at high altitude. Therefore, the participants had a significantly superior awareness of symptoms and prevention for AMS in the second period than in the first period of mountaineering. Also, no period effect was observed among the experienced participants in our study. Thus, this phenomenon could be classified as a learning effect. The weather, warmer during period 2, could be the other explanation for the period effect. Our trial was designed conservatively to avoid any possible bias against R. crenulata: we used a high dose of this agent, a longer period of drug preloading, and a steep ascent profile from the sea level. During the mountaineering trips, the following variables were controlled: rate of ascent, path, food type, and sleep altitude/environment.
In the present study, the environmental and medical resources available to study AMS were limited. We designed our study as a crossover trial for a key reason. Because each participant serves as his or her own control, it skillfully controls for the inherent individual susceptibility to AMS. Each person has his or her own personal tolerance for altitude change, and consequently, we calculated the percentage change of outcomes from his or her baseline to evaluate the effect of intervention or association with possible factors in parallel design. Using crossover design enabled us to measure the effect of intervention exactly, regardless of individual susceptibility. This design also had the benefits of increasing statistical power, given the limited sample size, and efficient control of the influence of confounding covariates.
Our study had several limitations. First, only 102 of the original 125 participants completed both trips. However, the statistical analyses were still adequately powered for three reasons: (1) the incidence of AMS was higher than what we had hypothesized using data generated in our previous survey. This was because most of our participants were inexperienced mountaineers, and their rate of controlled ascent was significantly higher than that in the previous study (4 h vs. 1–2 days). The participants were requested not to take acetazolamide or other possible prophylactic medications used by trekkers before mountaineering in previous surveys. (2) The sample size was estimated using the assumption that Rhodiola would reduce the incidence of AMS by 11% (36% to 25%) compared to placebo, but the results showed no difference between taking Rhodiola and placebo. Based on the data obtained in the present study, a sample of infinite size would be required to prove that Rhodiola had a significant prophylactic effect. (3) The sensitivity analysis showed that Rhodiola was not effective in preventing AMS regardless of the scenarios proposed (Figure 4). The second limitation is that half of the participants had a rescheduled second trip and they therefore took the study medication (or placebo) for 7 days before ascent and then on the first morning of ascent, for 8 days. Although they did not reach an altitude where AMS might be expected, they took study medication for 8 out of 9 days, and then they began medication once again 4 weeks later. Although these participants took double dosage of Rhodiola, their AMS incidence was not reduced. The third limitation is that the Rhodiola extract purified from the rhizome of R. crenulata was used to assure high concentration of active ingredients (2.38% salidroside and 0.44% p-tyrosol) in this study. However, the active ingredients for preventing AMS could have been lost during extraction and purification. Many Chinese tourists drink a decoction of Rhodiola rhizome to prevent AMS. The results of the present study do not exclude the possibility that this R. crenulata decoction may have a preventive effect on AMS. Last, only one dosage and one Rhodiola species were tested. Higher dosage or extracts from other species, such as Rhodiola rosea, Rhodiola kirilowii, Rhodiola sachalinensis, and Rhodiola algida, might be effective.
Studies have investigated different pharmacologic interventions to prevent AMS. Acetazolamide is effective for the prevention of AMS but it may be associated with paresthesias. Sumatriptan and gabapentin are beneficial but require further study. Antioxidants magnesium, Ginkgo biloba and Coca leaf products were not efficacious[5, 17]. In the Himalayan region, China, and Andean region of South America, using traditional applications of herbs for anti-high altitude illness is more common than using doctor prescription. For example, Coca leaf products were used more often among 62.8% of the surveyed travelers than acetazolamide prophylaxis (16.6%) for prevention, or other non-pharmacologic measures. Similar in China, 7% of 247 Chinese travelers on Qinghai-Tibet railroad took Rhodiola as a prophylaxis for AMS, but none used acetazolamide or dexamethasone, except one who had asthma. It was shown that coca leaf products did not prevent AMS, but increased the chance of AMS occurrence. Therefore, complementary and alternative medicines are omnipresent and popular, and should not be dismissed as "non-medications".
Our study is the first randomized, double-blind and controlled study of R. crenulata extract for AMS prophylaxis in humans though the current data does not demonstrate any prophylactic effects. Further studies will be needed to demonstrate the efficacy of R. crenulata decoction or other Rhodiola species in AMS prevention.
This randomized double-blind placebo control crossover trial demonstrated that the R. crenulata extract was not effective in reducing the incidence or severity of AMS. R. crenulata extract should not be recommended as a prophylactic for AMS.
This work was supported by the National Science Council, Taiwan, National Research Program for Biopharmaceuticals Grant (NSC 99-3114-B-182A-002) to T-F Chiu. Study medication and placebo were provided by Kaiser Pharmaceutical & Biotanico (Tainan, Taiwan). The training camp was provided Army Command Headquarter, Ministry of National Defense R.O.C. (The funders and the pharmaceutical factory had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript).
- Hackett PH, Roach RC: High-altitude illness. N Engl J Med. 2001, 345 (2): 107-114. 10.1056/NEJM200107123450206.View ArticlePubMedGoogle Scholar
- Imray C, Booth A, Wright A, Bradwell A: Acute altitude illnesses. BMJ. 2011, 343: d4943-10.1136/bmj.d4943.View ArticlePubMedGoogle Scholar
- Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM: Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med. 2005, 165 (3): 296-301. 10.1001/archinte.165.3.296.View ArticlePubMedGoogle Scholar
- Hackett PH, Rennie D, Levine HD: The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976, 2 (7996): 1149-1155.View ArticlePubMedGoogle Scholar
- Seupaul RA, Welch JL, Malka ST, Emmett TW: Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Ann Emerg Med. 2012, 59 (4): 307-317. 10.1016/j.annemergmed.2011.10.015.View ArticlePubMedGoogle Scholar
- Basnyat B, Murdoch DR: High-altitude illness. Lancet. 2003, 361 (9373): 1967-1974. 10.1016/S0140-6736(03)13591-X.View ArticlePubMedGoogle Scholar
- Dumont L, Mardirosoff C, Tramer MR: Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ. 2000, 321 (7256): 267-272. 10.1136/bmj.321.7256.267.View ArticlePubMedPubMed CentralGoogle Scholar
- Basnyat B, Gertsch JH, Holck PS, Johnson EW, Luks AM, Donham BP, Fleischman RJ, Gowder DW, Hawksworth JS, Jensen BT: Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol. 2006, 7 (1): 17-27. 10.1089/ham.2006.7.17.View ArticlePubMedGoogle Scholar
- Imray C, Wright A, Subudhi A, Roach R: Acute mountain sickness: pathophysiology, prevention, and treatment. Prog Cardiovasc Dis. 2010, 52 (6): 467-484. 10.1016/j.pcad.2010.02.003.View ArticlePubMedGoogle Scholar
- Panossian A, Wikman G, Sarris J: Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010, 17 (7): 481-493. 10.1016/j.phymed.2010.02.002.View ArticlePubMedGoogle Scholar
- Gertsch JH, Seto TB, Mor J, Onopa J: Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol. 2002, 3 (1): 29-37. 10.1089/152702902753639522.View ArticlePubMedGoogle Scholar
- Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS: Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004, 328 (7443): 797-10.1136/bmj.38043.501690.7C.View ArticlePubMedPubMed CentralGoogle Scholar
- van Patot MC, Keyes LE, Leadbetter G, Hackett PH: Ginkgo biloba for prevention of acute mountain sickness: does it work?. High Alt Med Biol. 2009, 10 (1): 33-43. 10.1089/ham.2008.1085.View ArticlePubMedGoogle Scholar
- Zhang ZJ, Tong Y, Zou J, Chen PJ, Yu DH: Dietary supplement with a combination of Rhodiola crenulata and Ginkgo biloba enhances the endurance performance in healthy volunteers. Chin J Integr Med. 2009, 15 (3): 177-183. 10.1007/s11655-009-0177-x.View ArticlePubMedGoogle Scholar
- Abidov M, Crendal F, Grachev S, Seifulla R, Ziegenfuss T: Effect of extracts from Rhodiola rosea and Rhodiola crenulata (Crassulaceae) roots on ATP content in mitochondria of skeletal muscles. Bull Exp Biol Med. 2003, 136 (6): 585-587.View ArticlePubMedGoogle Scholar
- Li T, Zhang H: Identification and comparative determination of rhodionin in traditional tibetan medicinal plants of fourteen Rhodiola species by high-performance liquid chromatography-photodiode array detection and electrospray ionization-mass spectrometry. Chem Pharm Bull (Tokyo). 2008, 56 (6): 807-814. 10.1248/cpb.56.807.View ArticleGoogle Scholar
- Salazar H, Swanson J, Mozo K, White AC, Cabada MM: Acute mountain sickness impact among travelers to Cusco. Peru. J Travel Med. 2012, 19 (4): 220-225. 10.1111/j.1708-8305.2012.00606.x.View ArticlePubMedGoogle Scholar
- De Bock K, Eijnde BO, Ramaekers M, Hespel P: Acute Rhodiola rosea intake can improve endurance exercise performance. Int J Sport Nutr Exerc Metab. 2004, 14 (3): 298-307.PubMedGoogle Scholar
- Hung SK, Perry R, Ernst E: The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine. 2011, 18 (4): 235-244. 10.1016/j.phymed.2010.08.014.View ArticlePubMedGoogle Scholar
- Lee SY, Li MH, Shi LS, Chu H, Ho CW, CTC: Rhodiola crenulata extract alleviates hypoxic pulmonary edema in rats. Evid Based Complement Alternat Med. 2013, 2013: 718739-PubMedPubMed CentralGoogle Scholar
- Swenson ER, Maggiorini M, Mongovin S, Gibbs JSR, Greve I, Mairbäurl H, Bärtsch P: Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. JAMA. 2002, 287 (17): 2228-2235. 10.1001/jama.287.17.2228.View ArticlePubMedGoogle Scholar
- Stream JO, Grissom CK: Update on high-altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness Environ Med. 2008, 19 (4): 293-303. 10.1580/07-WEME-REV-173.1.View ArticlePubMedGoogle Scholar
- Icard P, Saumon G: Alveolar sodium and liquid transport in mice. Am J Physiol. 1999, 277 (6): L1232-L1238.PubMedGoogle Scholar
- Looney MR, Sartori C, Chakraborty S, James PF, Lingrel JB, Matthay MA: Decreased expression of both the α1-and α2 -subunits of the Na-K-ATPase reduces maximal alveolar epithelial fluid clearance. Am J Physiol. 2005, 289 (1): L104-L110. 10.1152/ajpcell.00600.2004.View ArticleGoogle Scholar
- Zhang BC, Li WM, Guo R, Xu YW: Salidroside decreases atherosclerotic plaque formation in low-density lipoprotein receptor-deficient mice. Evid Based Complement Alternat Med. 2012, 2012: 607508-PubMedPubMed CentralGoogle Scholar
- Sun L, Isaak CK, Zhou Y: Salidroside and Tyrosol from Rhodiola protect H9c2 cell from ischemia/reperfusion-induced apoptosis. Life Sci. 2012, 91: 151-158. 10.1016/j.lfs.2012.06.026.View ArticlePubMedGoogle Scholar
- Chen SF, Tsai HJ, Hung TH, Chen CC, Lee CY, Wu CH, Wang PY, Liao NC: Salidroside improves behavioral and histological outcomes and reduces apoptosis via PI3K/Akt signaling after experimental traumatic brain injury. PLoS One. 2012, 7 (9): e45763-10.1371/journal.pone.0045763.View ArticlePubMedPubMed CentralGoogle Scholar
- Tu Y, Roberts L, Shetty K, Schneider SS: Rhodiola crenulata induces death and inhibits growth of breast cancer cell lines. J Med Food. 2008, 11 (3): 413-423. 10.1089/jmf.2007.0736.View ArticlePubMedGoogle Scholar
- Lee OH, Kwon YI, Apostolidis E, Shetty K, Kim YC: Rhodiola-induced inhibition of adipogenesis involves antioxidant enzyme response associated with pentose phosphate pathway. Phytother Res. 2011, 25 (1): 106-115. 10.1002/ptr.3236.View ArticlePubMedGoogle Scholar
- Qu ZQ, Zhou Y, Zeng YS, Lin YK, Li Y, Zhong ZQ, Chan WY: Protective effects of a Rhodiola crenulata extract and salidroside on hippocampal neurogenesis against streptozotocin-induced neural injury in the rat. PLoS One. 2012, 7 (1): e29641-10.1371/journal.pone.0029641.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee SY, Shi LS, Chu H, Li MH, Ho CW, Lai FY, Huang CY, Chang TC: Rhodiola crenulata and its bioactive components, salidroside and tyrosol, reverse the hypoxia-induced reduction of plasma-membrane-associated Na. K-ATPase expression via inhibition of ROS-AMPK-PKC ξ Pathway. Evid Based Complement Alternat Med. 2013, 2013: 284150-PubMedGoogle Scholar
- Wu TY, Ding SQ, Zhang SL, Duan JQ, Li BY, Zhan ZY, Wu QL, Baomu S, Liang BZ, Han SR, Jie YL, Li G, Sun L, Kayser B: Altitude illness in Qinghai–Tibet railroad passengers. High Alt Med Biol. 2010, 11 (3): 189-198. 10.1089/ham.2009.1047.View ArticlePubMedGoogle Scholar
- Wang S, Wang FP: [Studies on the chemical components of Rhodiola crenulata]. Yao Xue Xue Bao. 1992, 27 (2): 117-120.PubMedGoogle Scholar
- Wang S, You XT, Wang FP: [HPLC determination of salidroside in the roots of Rhodiola genus plants]. Yao Xue Xue Bao. 1992, 27 (11): 849-852.PubMedGoogle Scholar
- Roach RC, Bartsch P, Hackett PH, Oelz O: Hypoxia and Molecular Medicine: Proceedings of the 8th International Hypoxia Symposium: The Lake Louise Acute Mountain Sickness Scoring System. 1993Google Scholar
- Wang SH, Chen YC, Kao WF, Lin YJ, Chen JC, Chiu TF, Hsu TY, Chen HC, Liu SW: Epidemiology of acute mountain sickness on Jade Mountain, Taiwan: an annual prospective observational study. High Alt Med Biol. 2010, 11 (1): 43-49. 10.1089/ham.2009.1063.View ArticlePubMedGoogle Scholar
- Mairer K, Wille M, Bucher T, Burtscher M: Prevalence of acute mountain sickness in the Eastern Alps. High Alt Med Biol. 2009, 10 (3): 239-245. 10.1089/ham.2008.1091.View ArticlePubMedGoogle Scholar
- Pesce C, Leal C, Pinto H, González G, Maggiorini M, Schneider M, Bärtsch P: Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol. 2005, 6 (2): 158-166. 10.1089/ham.2005.6.158.View ArticlePubMedGoogle Scholar
- Ziaee V, Yunesian M, Ahmadinejad Z, Halabchi F, Kordi R, Alizadeh R, Afsharjoo HR: Acute mountain sickness in Iranian trekkers around Mount Damavand (5671 m) in Iran. Wilderness Environ Med. 2003, 14 (4): 214-219. 10.1580/1080-6032(2003)14[214:AMSIIT]2.0.CO;2.View ArticlePubMedGoogle Scholar
- Gaillard S, Dellasanta P, Loutan L, Kayser B: Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up. High Alt Med Biol. 2004, 5: 410-419. 10.1089/ham.2004.5.410.View ArticlePubMedGoogle Scholar
- Vardy J, Vardy J, Judge K: Can knowledge protect against acute mountain sickness?. J Public Health (Oxf). 2005, 27: 366-370. 10.1093/pubmed/fdi060.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/298/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.